Daehwa Pharmaceutical accelerates to launch the world’s first oral paclitaxel antibody

Published: 2016-02-16 15:27:07

Updated: 2016-02-16 15:27:07

Daehwa Pharmaceutical announced it applied manufacturing, sales and product approvals of ‘DHP107,’ the world’s first oral paclitaxel-type modified drug, to the Ministry of Food and Drug Safety on the 12^th.

DHP107 proved equivalence(non-inferior model) in safety and evaluation variables of effectiveness – such as progression-fee survival(PFS) and objective response rate(ORP) – compared to pacli...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.

Daehwa Pharmaceutical accelerates to launch the world’s first oral paclitaxel antibody

Daehwa Pharmaceutical announced it applied manufacturing, sales and product approvals of ‘DHP107,’ the world’s first oral paclitaxel-type modified drug, to the Ministry of Food and Drug Safety on the 12th.

Fees

Daehwa Pharmaceutical announced it applied manufacturing, sales and product approvals of ‘DHP107,’ the world’s first oral paclitaxel-type modified drug, to the Ministry of Food and Drug Safety on the 12^th.